




PHARMACEUTICAL 2022

SCYNEXIS INC
Rank 328 of 466





PHARMACEUTICAL 2022

SCYNEXIS INC
Rank 328 of 466



The relative strengths and weaknesses of SCYNEXIS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SCYNEXIS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 29% points. The greatest weakness of SCYNEXIS INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 119% points.

The company's Economic Capital Ratio, given in the ranking table, is 38%, being 40% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	109,377
Cost of Goods Sold	0
Intangible Assets	1,056
Liabilities, Current	13,616
Liabilities, Non-Current	6,549
Other Assets	9,291
Other Compr. Net Income	0
Other Expenses	-2,776
Other Liabilities	58,414
Other Net Income	24,884
Other Revenues	13,163
Property and Equipment	113
Research and Development	23,773
Selling, General and Administrative Expense	49,916

Output Variable	Value in 1000 USD
Assets	119,837
Liabilities	78,579
Expenses	70,913
Revenues	13,163
Stockholders Equity	41,258
Net Income	-32,866
Comprehensive Net Income	-32,866
Economic Capital Ratio	38%